Bluejay Therapeutics

Bluejay Therapeutics is a biotechnology company focused on developing innovative treatments for infectious diseases, with a primary emphasis on chronic Hepatitis B Virus (HBV) infection. The company operates in the biopharmaceutical sector, aiming to address the unmet medical needs of patients suffering from chronic HBV. Bluejay's business model revolves around the research, development, and commercialization of novel therapeutic solutions. The company has exclusively licensed global rights to three assets that are either best-in-class or first-in-class, positioning itself at the forefront of HBV treatment innovation. Bluejay generates revenue through the development and potential future sales of these therapeutic products. The company's target clients include healthcare providers, hospitals, and patients affected by chronic HBV. By focusing on the reduction of Hepatitis B surface antigen (HBsAg) and the restoration of adaptive immunity, Bluejay aims to achieve a functional cure for chronic HBV infection. The market for HBV treatments is substantial, given the global prevalence of the disease and the significant mortality associated with it. Bluejay Therapeutics is committed to advancing its pipeline of therapies to improve patient outcomes and address this critical public health issue.

Keywords: chronic HBV, Hepatitis B, antigen reduction, immune restoration, biotechnology, biopharmaceutical, innovative treatments, functional cure, infectious diseases, healthcare.